دورية أكاديمية
أعرض في EDS

Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.

التفاصيل البيبلوغرافية
العنوان: Prevalence of anti-lymphocyte IgM autoantibodies driving complement activation in COVID-19 patients.
المؤلفون: Pérez-Díez A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Liu X; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Calderon S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Bennett A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Lisco A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Kellog A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Galindo F; Division of Clinical Research, NIAID, NIH, Bethesda, MD, United States., Memoli MJ; Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Rocco JM; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Epling BP; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Laidlaw E; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Sneller MC; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Manion M; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States., Wortmann GW; Section of Infectious Diseases, MedStar Washington Hospital Center, Washington, DC, United States., Poon R; Division of Hospital Medicine, Georgetown University Medical Center, Washington, DC, United States., Kumar P; Division of Infectious Diseases and Tropical Medicine, Georgetown University Medical Center, Washington, DC, United States., Sereti I; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, United States.
المصدر: Frontiers in immunology [Front Immunol] 2024 Apr 17; Vol. 15, pp. 1352330. Date of Electronic Publication: 2024 Apr 17 (Print Publication: 2024).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: COVID-19*/immunology , COVID-19*/blood , Immunoglobulin M*/blood , Immunoglobulin M*/immunology , Autoantibodies*/blood , Autoantibodies*/immunology , Complement Activation*/immunology , SARS-CoV-2*/immunology, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Lymphocytes/immunology ; Prevalence ; CD4-Positive T-Lymphocytes/immunology ; Lymphopenia/immunology ; Lymphopenia/blood ; Complement C3b/immunology
مستخلص: Introduction: COVID-19 patients can develop autoantibodies against a variety of secreted and membrane proteins, including some expressed on lymphocytes. However, it is unclear what proportion of patients might develop anti-lymphocyte antibodies (ALAb) and what functional relevance they might have.
Methods: We evaluated the presence and lytic function of ALAb in the sera of a cohort of 85 COVID-19 patients (68 unvaccinated and 17 vaccinated) assigned to mild (N=63), or moderate/severe disease (N=22) groups. Thirty-seven patients were followed-up after recovery. We also analyzed in vivo complement deposition on COVID-19 patients' lymphocytes and examined its correlation with lymphocyte numbers during acute disease.
Results: Compared with healthy donors (HD), patients had an increased prevalence of IgM ALAb, which was significantly higher in moderate/severe disease patients and persisted after recovery. Sera from IgM ALAb+ patients exhibited complement-dependent cytotoxicity (CDC) against HD lymphocytes. Complement protein C3b deposition on patients' CD4 T cells was inversely correlated with CD4 T cell numbers. This correlation was stronger in moderate/severe disease patients.
Discussion: IgM ALAb and complement activation against lymphocytes may contribute to the acute lymphopenia observed in COVID-19 patients.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Pérez-Díez, Liu, Calderon, Bennett, Lisco, Kellog, Galindo, Memoli, Rocco, Epling, Laidlaw, Sneller, Manion, Wortmann, Poon, Kumar and Sereti.)
References: Ann Intern Med. 2022 Jul;175(7):969-979. (PMID: 35605238)
Cell Rep Med. 2021 Jun 15;2(6):100321. (PMID: 34075365)
Clin Infect Dis. 2015 Mar 1;60(5):693-702. (PMID: 25416753)
N Engl J Med. 2020 Jul 9;383(2):120-128. (PMID: 32437596)
J Exp Med. 2021 Mar 1;218(3):. (PMID: 33231615)
J Virol. 2020 Mar 17;94(7):. (PMID: 31996437)
Brain Behav Immun. 2021 Mar;93:415-419. (PMID: 33359380)
Nature. 2020 Dec;588(7836):146-150. (PMID: 32726800)
Front Immunol. 2016 Jun 06;7:198. (PMID: 27375614)
Front Immunol. 2022 Feb 17;13:815833. (PMID: 35250994)
Cell. 2020 May 28;181(5):1036-1045.e9. (PMID: 32416070)
N Engl J Med. 2020 Apr 23;382(17):e38. (PMID: 32268022)
Signal Transduct Target Ther. 2022 Sep 14;7(1):318. (PMID: 36100602)
Front Immunol. 2020 Oct 02;11:587517. (PMID: 33123171)
Int J Med Sci. 2020 Jun 18;17(11):1522-1531. (PMID: 32669955)
N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
Nature. 2021 Jul;595(7866):283-288. (PMID: 34010947)
J Exp Med. 2022 Jun 6;219(6):. (PMID: 35420627)
J Transl Med. 2021 Dec 30;19(1):524. (PMID: 34965855)
Sci Immunol. 2021 May 13;6(59):. (PMID: 34446527)
Sci Immunol. 2021 Apr 7;6(58):. (PMID: 33827897)
Nature. 2022 Nov;611(7934):139-147. (PMID: 36044993)
Front Immunol. 2022 Mar 10;13:862652. (PMID: 35359981)
Nat Immunol. 2023 Apr;24(4):604-611. (PMID: 36879067)
J Infect. 2020 Aug;81(2):318-356. (PMID: 32283159)
Nat Rev Immunol. 2022 Feb;22(2):77-84. (PMID: 34912108)
Nat Rev Rheumatol. 2021 Jun;17(6):315-332. (PMID: 33903743)
Immunity. 2013 Dec 12;39(6):1143-57. (PMID: 24315997)
Signal Transduct Target Ther. 2020 Mar 27;5(1):33. (PMID: 32296069)
Cell. 2022 Mar 3;185(5):881-895.e20. (PMID: 35216672)
J Clin Invest. 2021 Dec 15;131(24):. (PMID: 34710063)
Cell Rep Med. 2021 May 18;2(5):100288. (PMID: 33969321)
Life Sci Alliance. 2021 Sep 9;4(11):. (PMID: 34504035)
Nat Commun. 2021 Sep 14;12(1):5417. (PMID: 34521836)
Clin Exp Immunol. 2021 Aug;205(2):99-105. (PMID: 34082475)
Front Immunol. 2022 Jan 14;12:799558. (PMID: 35095880)
Nat Immunol. 2010 Sep;11(9):862-71. (PMID: 20694009)
J Clin Invest. 2020 Oct 1;130(10):5326-5337. (PMID: 32634122)
Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508)
فهرسة مساهمة: Keywords: COVID-19; anti-lymphocyte Ab; autoantibodies; complement activation; complement deposition; complement-dependent cytotoxicity; convalescent COVID-19; lymphopenia
المشرفين على المادة: 0 (Immunoglobulin M)
0 (Autoantibodies)
80295-43-8 (Complement C3b)
تواريخ الأحداث: Date Created: 20240502 Date Completed: 20240502 Latest Revision: 20240503
رمز التحديث: 20240503
مُعرف محوري في PubMed: PMC11061367
DOI: 10.3389/fimmu.2024.1352330
PMID: 38694513
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2024.1352330